Examkin

Question

Difficulty: MediumCardiovascular System

A 72-year-old man visits the outpatient clinic reporting a four-week history of progressively worsening shortness of breath and a persistent, dry cough. His medical history includes coronary artery disease, ischemic cardiomyopathy with a left ventricular ejection fraction of 35%, paroxysmal atrial fibrillation, and mild chronic obstructive pulmonary disease. He smoked cigarettes for 30 years but quit a decade ago. Current medications include lisinopril, metoprolol succinate, spironolactone, apixaban, and an antiarrhythmic agent initiated six months ago to maintain normal sinus rhythm. Vital signs show a blood pressure of 128/78 mm Hg, a pulse of 68/min, and a respiratory rate of 20/min. Pulse oximetry is 91% on room air. Jugular venous pressure is normal at 6 cm H2OH_2O. Lung auscultation reveals bilateral fine, "Velcro-like" inspiratory crackles, but no wheezing or rhonchi. Cardiac examination shows a regular rate and rhythm with no murmurs or gallops. There is no lower extremity edema. A high-resolution computed tomography scan of the chest demonstrates bilateral ground-glass opacities and reticular interstitial thickening. Which of the following is the most appropriate next step in the management of this patient?

  1. A
    Increase in the daily dosage of oral furosemide
  2. B
    Administration of a short-acting bronchodilator and oral corticosteroids
  3. C
    Initiation of empiric oral levofloxacin therapy
  4. Discontinuation of the rhythm-control medicationAnswer
  5. E
    Measurement of serum thyroid-stimulating hormone and thyroxine levels

Answer

Discontinuation of the rhythm-control medication
The patient's clinical presentation of progressive dyspnea, nonproductive cough, bilateral fine inspiratory crackles, and ground-glass opacities on imaging, in the setting of a recently initiated antiarrhythmic medication, is classic for amiodarone-induced pulmonary toxicity. Amiodarone is a Class III antiarrhythmic commonly used for rhythm control in atrial fibrillation, particularly in patients with structural heart disease like ischemic cardiomyopathy. Pulmonary toxicity is a serious adverse effect that can manifest months to years after initiation. Because the patient lacks signs of volume overload (normal jugular venous pressure, no edema) or active bronchospasm, heart failure and chronic obstructive pulmonary disease exacerbations are unlikely. The most critical next step is the immediate cessation of the offending drug.

Step-by-Step Solution

1
Analyze the patient's medication history and symptom timeline.
The patient was started on a rhythm-control drug for atrial fibrillation 6 months ago (likely amiodarone given the structural heart disease) and now has a progressive dry cough and dyspnea.
Identifying the chronological relationship between new medications and symptom onset is essential for diagnosing adverse drug effects.
2
Differentiate the etiology of respiratory distress using physical exam and imaging findings.
Normal jugular venous pressure and absent edema rule against cardiogenic pulmonary edema. Absent wheezing rules against a COPD exacerbation. Fine crackles and CT findings of ground-glass opacities strongly indicate an interstitial lung process.
Patients with multiple comorbidities (HF, COPD, arrhythmias) require careful physical exam interpretation to prevent misdiagnosis of their acute presentation.
3
Determine the necessary therapeutic intervention.
The clinical picture is highly specific for amiodarone-induced pulmonary toxicity. The immediate necessary action is to stop the offending agent.
Continued exposure to amiodarone in the presence of pulmonary toxicity can lead to irreversible pulmonary fibrosis and potentially fatal acute respiratory distress syndrome.

Key Concept

Amiodarone-induced pulmonary toxicity commonly presents with progressive dyspnea, nonproductive cough, fine inspiratory crackles, and bilateral interstitial opacities on imaging. The cornerstone of management is immediate discontinuation of the medication.
Rate this question

Topics

Cardiovascular System

More questions from this topic